The FDA has approved Akeso Inc.’s penpulimab-kcqx in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or metastatic NPC.

CPTx GmbH, a pioneer in the therapeutic development and manufacturing of novel medicines built with single-stranded DNA, has ...

Debiopharm and Oncodesign Services have signed a license agreement for the use of Debiopharm’s AbYlink technology for ...

CN Bio, which offers Organ-on-a-chip systems, has formed a strategic partnership with Pharmaron, a life sciences R&D service ...

Under Shinomiya’s leadership, Asahi Kasei’s Healthcare Sector will further advance its portfolio and global presence.

Mosaic Therapeutics Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new ...

Hansa Biopharma AB announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately ...

The U.S. Food and Drug Administration (FDA) has approved Ferring Pharmaceuticals’ drug product manufacturing hub in ...

To meet growing pharmaceutical needs for biologics and complex therapeutics, EVERSANA also increased its cold chain ...

PCI Pharma Services is acquiring an entire equity stake in Ajinomoto Althea Inc. (Althea), a U.S.-based sterile fill-finish ...

Payman Khales is appointed CEO as Joseph Dziedzic will retire. Integer Holdings Corporation, a medical device contract ...

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s ...